SignaCor Therapeutics Secures €288K Funding To Advance Heart Disease Treatment

The investment is part of the Discovery Spark programme at Discovery Park, which supports innovations in cardiovascular health. It will form part of a €1.1 million (£1 million) Seed round, expected to close in April 2026.

Founded in 2024 as a clinical-stage drug development company spun out from Queen’s University Belfast, SignaCor is focused on developing first-in-class therapies for HCM, a genetic disorder where heart muscle thickening impairs blood flow and affects approximately 1 in 500 people in the UK.

Led by CEO Darach Neeson and CSO Dr Chris Watson, SignaCor is pioneering ‘Cardiaza’, the first therapy that leverages DNA methylation to address multiple underlying causes of symptomatic HCM, including established fibrosis, with the goal of reversing heart damage and improving patient quality of life.

Read Also - YC-Backed Escape Raises €15.4M Series A Led By Balderton For AI-Powered Offensive Security Platform

The funding comes after SignaCor won Discovery Spark’s startup growth programme, which included seven weeks of specialist-led mentoring and concluded with a pitch day at Zinc’s London offices.

Darach Neeson, CEO at SignaCor, says: “The Spark programme’s content was exceptional value-filled insights from UK life science industry experts and meaningful investor engagement. The lessons learned have influenced our strategy, and we would absolutely recommend it to other founders. We are excited to now join Zinc’s portfolio of innovative life science companies. This funding will allow us to execute our Phase 2a trial plans and advance our regulatory strategy, bringing us closer to delivering a new treatment for patients with limited treatment options.”

About SignaCor Therapeutics

SignaCor Therapeutics is a clinical-stage drug development company spun out from Queen’s University Belfast, focused on cardiac disease treatments. The company is pioneering first-in-class therapies for symptomatic hypertrophic cardiomyopathy (HCM) targeting the underlying disease pathology rather than just managing symptoms, aiming to improve patient outcomes and quality of life.